Vaccines
Pfizer has announced it received Breakthrough Therapy Designation from the FDA for its vaccine candidate intended to prevent infections caused by the respiratory syncytial virus (RSV).
Moderna reported positive interim results from the Phase II/III KidCOVE trial of its mRNA COVID-19 vaccine for children six months to under two years and two to six years of age.
Aerium Therapeutics has officially launched following a successful Series A funding round led by seed investor Omega Funds.
Sir Mene Pangalos said the company was considering not submitting it to the FDA if it finds it is “banging its head against a brick wall indefinitely.”
Codagenix is entering the vaccine arena with a possible new frontrunner in protection: CoviLiv. It’s an intranasal COVID vaccine that provides hope against subvariants.
Alnylam is suing Moderna and Pfizer over patent infringements related to its lipid techQnology that have been foundational to the success of the mRNA-based COVID-19 vaccines.
Robert Hollingsworth, PhD, a former Pfizer executive who oversaw the development of cancer vaccines and immunotherapeutics, has taken on the role of the CSO at Shoreline Biosciences.
Now that Omicron is becoming less common, its sister variant, BA.2, seems to be surging worldwide and in the U.S. For that and more, continue reading.
Araclon Biotech of Spain revealed positive data from the first part of a phase II trial for its immunotherapeutic vaccine to prevent Alzheimer’s disease- ABvac40.
The Russian invasion of Ukraine has hampered Ukrainian research to develop new treatments for infection from the SARS-CoV-2 virus and increased the risk of spreading virulent pathogens.
PRESS RELEASES